Диссертация (1140384), страница 28
Текст из файла (страница 28)
Jacome, P.S. Araujo, M.A.V. Maciel //Revista da Sociedade Brasileira de Medicina Tropical. – 2017. – Vol. 50, № 6. – P.764–768.214.Song, W. Carbapenem inactivation method: accurate detection and easyinterpretation of carbapenemase production in Enterobacteriaceae and Pseudomonasspp / W. Sng, H. Kim, J. Kim,. H.S. Kim, D.H. Shin, S. Shin, M. Park // Annals ofClinical Microbiology and Antimicrobials. – 2016. – Vol. 19, № 4. – P. 83-87.215.Soundararajan, G. Understanding carbapenem translocation through OccD3(OpdP) of Pseudomonas aeruginosa / G. Soundararajan, S.P. Bhamidimarri, M.Winterhalter // ACS Chemical Biology. – 2017. – Vol. 12, № 6.
– P. 1656-1664.216.Srikumar, R. Expression of Pseudomonas aeruginosa multidrug efflux pumpsMexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichiacoli strain / R. Srikumar, T. Kon, N. Gotoh, K. Poole // Antimicrobial Agents andChemotherapy. – 1998. – Vol. 42, № 1. – P. 65–71.217.Stover, C.
K. Complete genome sequence of Pseudomonas aeruginosa PAO1,an opportunistic pathogen / C. K. Stover, X.Q. Pham, A. L. Erwin, S. D. Mizoguchi,P. Warrener, M.J. Hickey, F.S. Brinkman, W.O. Hufnagle, D.J. Kowalik, M.Lagrou, R.L. Garber, L. Goltry, E. Tolentino, S. Westbrock-Wadman, Y. Yuan, L.L.Brody, S.N. Coulter, K.R. Folger, A. Kas, K. Larbig, R. Lim, K. Smith, D. Spencer,G.K. Wong, Z. Wu, I.T.
Paulsen, J. Reizer, M.H. Saier, R.E. Hancock, S. Lory,M.V. Olson // Nature. – 2000. – Vol. 406, № 6799. – P. 959-964.173218.Strateva, T. Pseudomonas aeruginosa - a phenomenon of bacterial resistance / T.Strateva, D. Yordanov // Journal of Medical Microbiology. – 2009. – Vol. 58, № 9.– P. 1133–1148.219.Suci, P.A. Investigation of ciprofloxacin penetration into Pseudomonasaeruginosa biofilms // P.A. Suci, M.W. Mittelman, F.P. Yu, G.G.
Geesey //Antimicrobial agents and chemotherapy. – 1994. – Vol. 38, № 9. – P. 2125–2133.220.Sun, Q. Insertion sequence ISRP10 inactivation of the oprD gene in imipenem-resistant Pseudomonas aeruginosa clinical isolates / Q. Sun, Z. Ba, G. Wu, W.Wang, S. Lin, H. Yang // International Journal of Antimicrobial Agents. – 2016. –Vol. 47, № 5. – P. 375–379.221.Szuplewska, M.
Mobility and generation of mosaic non-autonomous transposonsby Tn3-derived inverted-repeat miniature elements (TIMEs) / M. Szuplewska, M .Ludwiczak, K. Lyzwa, J. Czarnecki, D. Bartosik // PLoS One. – 2014. – Vol. 9, №8. – e105010.222.Tam, V.H. Prevalence of AmpC over-expression in bloodstream isolates ofPseudomonas aeruginosa / V.H. Tam, A.N. Schilling, M.T. LaRocco, L.O. Gentry,K.
Lolans, J.P. Quinn, K.W. Garey // Clinical Microbiology and Infection. – 2007. –Vol. 13, № 4. – P. 413–418.223.Tam, V.H. Prevalence, mechanisms, and risk factors of carbapenem resistance inbloodstream isolates of Pseudomonas aeruginosa // V.H. Tam, K.T. Chang, M.T.LaRocco, A.N. Schilling, S.K. McCauley, K.
Poole, K.W. Garey // DiagnosticMicrobiology Infectious Disease. – 2007. – Vol. 58, № 3. – P. 309–314.224.Tamber, S. Role of the novel OprD family of porins in nutrient Uptake inPseudomonas aeruginosa / S. Tamber, M.M. Ochs, R.E.W. Hancock // Journal ofBacteriology.
– 2006. – Vol. 188, № 1. – P. 45-54.225.Tegos, G.P. Microbial efflux pump inhibition: tactics and strategies / G.P.Tegos, M. Haynes, J.J. Strouse, M.T. Khan, C.G. Bologa, T.I. Oprea, L.A. Sklar //Current pharmaceutical design. – 2011. – Vol. 17, № 13. – P. 1291–1302.174226.The Clinical Laboratory Standards Institute (CLSI) [Электронный ресурс] //Performance Standards for antimicrobial susceptibility testing, 28th Edition, 2018.
–P. 38. - URL: http://em100.edaptivedocs.info/dashboard.aspx (дата обращения:10.01.2018).227.Thomson, K.S. Extended-Spectrum-β-Lactamase, AmpC, and carbapenemaseissues. / K.S. Thomson // Journal of Clinical Microbiology. – 2010. – Vol. 48, № 4.– P. 1019–1025.228.Tomas, M. Efflux pumps, OprD porin, AmpC β-lactamase, and multiresistancein Pseudomonas aeruginosa isolates from cystic fibrosis patients / M. Tomas, M.Doumith, M.
Warner, J.F. Turton, A. Beceiro, G. Bou, D.M. Livermore, N.Woodford // Antimicrobial Agents and Chemotherapy. – 2010. – Vol. 54, № 5. – P.2219–2224.229.Trias, J. Decreased outer membrane permeability in imipenem-resistant mutantsof Pseudomonas aeruginosa / J. Trias, J. Dufresne, R.C. Levesque, H. Nikaido //Antimicrobial Agents and Chemotherapy. – 1989. – Vol. 33, № 8. – P. 1202–1206.230.Trias, J.
Outer membrane protein D2 catalyzes facilitated diffusion ofcarbapenems and penems through the outer membrane of Pseudomonas aeruginosa /J. Trias, H. Nikaido // Antimicrobial Agents and Chemotherapy. – 1990. – Vol. 34,№1. – P. 52–57.231.Trimble, M.J. Polymyxin: alternative mechanisms of action and resistance /M.J. Trimble, P. Mlynarcik, M.
Kolar, R.E. Hancock // Cold Spring HarborPerspectives in Medicine – 2016. – Vol. 6, № 10. – a025288.232.Uwate, M. Two routes of MexS-MexT-mediated regulation of MexEF-OprN andMexAB-OprM efflux pump expression in Pseudomonas aeruginosa / M. Uwate,Y.K.
Ichise, A. Shirai, T. Omasa, T. Nakae, H. Maseda // Microbiology andImmunology. – 2013. – Vol. 57, №4. – P. 263–272.233.Valentini, M. Lifestyle transitions and adaptive pathogenesis of Pseudomonasaeruginosa. M. Valentini, D. Gonzalez, D.A. Mavridou, A. Filloux / CurrentOpinion in Microbiology. – 2017. – V. 18, №41. – P. 15–20.175234.Vidal-Aroca, F. Use of resazurin to detect mefloquine as an efflux-pumpinhibitor in Pseudomonas aeruginosa and Escherichia coli / F. Vidal-Aroca, A.Meng, T. Minz, M.G.
Page, J. Dreier // Journal of Microbiology Methods. – 2009. –Vol. 79, № 2. – P. 232–237.235.Vollan, H.S. In silico structure and sequence analysis of bacterial porins andspecific diffusion channels for hydrophilic molecules: conservation, multimericityand multifunctionality / H.S.
Vollan, T. Tannas, Vriend ., G. Bukholm //International Journal of Molecular Sciences – 2016. – Vol. 17, № 4. – pii: E599.236.Walther-Rasmussen, J. OXA-type carbapenemases // J. Walther-Rasmussen, N.Hoiby // Journal of Antimicrobial Chemotherapy. – 2006. – Vol. 57, № 3. – P. 373–383.237.Wei, W.J.
New Delhi metallo-β-lactamase-mediated carbapenem resistance:origin, diagnosis, treatment and public health concern / W.J. Wei, H.F. Yang, Y. Ye,J.B. Li // Chinese medical journal. – 2015. – Vol. 128, №14. – P. 1969–1976.238.Weiner, L.M. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare SafetyNetwork at the Centers for Disease Control and Prevention, 2011–2014 / L.M.Weiner, A. K.
Webb, B. Limbago, M.A. Dudeck, J. Patel, A.J. Kallen, D. M. Sievert// Infection control and hospital epidemiology. – 2016. – Vol. 37, № 11. – P. 1288–1301.239.Wendel, A.F. Detection and termination of an extended low-frequency hospitaloutbreak of GIM-1–producing Pseudomonas aeruginosa ST111 in Germany / A.F.Wendel, S. Kolbe-Busch, S. Ressina, R. Schulze-Robbecke, D. Kindgen-Milles, C.Lorenz, C.R.
MacKenzie // American journal of infection control. – 2015. – Vol. 43,№ 6. – P. 635–639.240.Wöckel, W. Pseudomonas aeruginosa (Bacterium pyocyaneum) infection / W.Wöckel // Ergebnisse der allgemeinen Pathologie und pathologischen Anatomie. –1967. – № 48. – P. 102–170.176241.Wolkowicz, T. Distribution of carbapenem resistance mechanisms inPseudomonas aeruginosa isolates among hospitalised children in Poland:Characterisation of two novel insertion sequences disrupting the oprD gene / T.Wolkowicz, J.A. Patzer, W. Kaminska, R.
Gierczynski, D. Dzierzanowska // Journalof Global Antimicrobial Resistance. – 2016. – № 7. – P. 119– 125.242.Wolter, D.J. Insertional inactivation of oprD in clinical isolates of Pseudomonasaeruginosa leading to carbapenem resistance / D.J. Wolter, N.D. Hanson, P.D.Lister // FEMS Microbiology Letters. - 2004.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
